BiotechTube

Micafungin

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Antifungal Prophylaxis

Conditions

Antifungal Prophylaxis, Haemopathy

Trial Timeline

Jul 3, 2014 → Jan 27, 2016

NCT ID
NCT02127788

About Micafungin

Micafungin is a pre-clinical stage product being developed by Astellas Pharma for Antifungal Prophylaxis. The current trial status is completed. This product is registered under clinical trial identifier NCT02127788. Target conditions include Antifungal Prophylaxis, Haemopathy.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (15)

NCT IDPhaseStatus
NCT03174457Pre-clinicalCompleted
NCT03102658ApprovedCompleted
NCT02440178Phase 2Completed
NCT03421002Phase 2Completed
NCT02678598Pre-clinicalCompleted
NCT02127788Pre-clinicalCompleted
NCT02646800ApprovedTerminated
NCT02646774ApprovedTerminated
NCT02057289Phase 1Terminated
NCT01982071ApprovedTerminated
NCT01135589ApprovedUNKNOWN
NCT00606268Phase 1Completed
NCT00608335Phase 1Completed
NCT00818584Phase 1Completed
NCT00842504Phase 1Completed

Competing Products

1 competing product in Antifungal Prophylaxis

See all competitors
ProductCompanyStageHype Score
Itraconazole + Vfend - voriconazolePfizerPhase 3
76

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85